Biomics are now due to report on in vivo studies which will pave the way for a trial in HBV. The go ahead from the FDA for TT-034 will also enhance the decision to proceed.
Holders, having had the benefit of the latest very successful CR, would likely be more happy with the rises to come if BLTOB don't dilute.
bltob needs ddrnai, page-4
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)